EASI Score (Eczema Area and Severity Index)
Quantifies atopic dermatitis severity across four body regions. EASI >=16 = severe eczema; guides systemic/biologic therapy eligibility (dupilumab).
Score interpretation
→ Emollients (multiple daily applications); mild-moderate topical corticosteroids; trigger avoidance; topical calcineurin inhibitors for face/folds; patient education
→ Potent topical steroids; wet wrapping; consider dupilumab or ciclosporin if EASI >=16 and prior therapy failed; phototherapy (NB-UVB); dermatology referral
→ Urgent dermatology; dupilumab 300mg SC fortnightly (NICE-approved for severe AD); alternatively JAK inhibitors (upadacitinib, abrocitinib); baseline FBC, LFTs, lipids; infection screen before starting immunosuppression
Interpretation bands for the EASI Eczema Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata) · JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant
- Tralokinumab · IL-13 Inhibitor — Atopic Eczema
- Abrocitinib · JAK1 Inhibitor — Atopic Eczema
- Lebrikizumab · IL-13 Inhibitor — Atopic Eczema
- Dupilumab · Biologic (IL-4 / IL-13 receptor antagonist)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.